Trevogrumab

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Trevogrumab (INN; development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. It is often used with Garetosmab. Trevogrumab is a fully human monoclonal antibody that functions as a selective inhibitor of myostatin (GDF8), a key negative regulator of skeletal muscle growth and mass.

By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors (ActRIIA/B), thereby reducing myostatin-mediated signaling and allowing increased muscle growth and preservation. This drug was developed by Regeneron Pharmaceuticals, Inc.

Trevogrumab (INN; development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. It is often used with Garetosmab. Trevogrumab is a fully human monoclonal antibody that functions as a selective inhibitor of myostatin (GDF8), a key negative regulator of skeletal muscle growth and mass.

By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors (ActRIIA/B), thereby reducing myostatin-mediated signaling and allowing increased muscle growth and preservation. This drug was developed by Regeneron Pharmaceuticals, Inc.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1368853830 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.